Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone Mechanism in Bipolar Disorder
NCT03902613Phase 4Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Feb 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lurasidone in bipolar disorder (BD), sponsored by New York State Psychiatric Institute. Primary endpoint: Montgomery Asberg Depression Rating Scale at 15 minutes. Started Feb 2019; status: completed.
02
Drugs
lurasidone
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT03902613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03902613.